Investigational Drug Information for Seltorexant
What is the drug development status for Seltorexant?
Seltorexant is an investigational drug.
There have been 19 clinical trials for Seltorexant.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 25th 2024.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Janssen Research & Development, LLC, Minerva Neurosciences, and [disabled in preview].
There are three US patents protecting this investigational drug and fifty-nine international patents.
Summary for Seltorexant
| US Patents | 3 |
| International Patents | 59 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2024-07-25) |
| Vendors | 8 |
Recent Clinical Trials for Seltorexant
| Title | Sponsor | Phase |
|---|---|---|
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Janssen Research & Development, LLC | PHASE3 |
| A Study of Seltorexant in Participants With Probable Alzheimer's Disease | Janssen Research & Development, LLC | Phase 2 |
| A Study of JNJ-42847922 (Seltorexant) in Healthy Participants | Janssen Research & Development, LLC | Phase 1 |
Clinical Trial Summary for Seltorexant
Top disease conditions for Seltorexant
Top clinical trial sponsors for Seltorexant
US Patents for Seltorexant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Seltorexant | ⤷ Start Trial | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | Janssen Pharmaceutica NV , Janssen Research and Development LLC | ⤷ Start Trial |
| Seltorexant | ⤷ Start Trial | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | Janssen Pharmaceutica (BE) | ⤷ Start Trial |
| Seltorexant | ⤷ Start Trial | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | Janssen Pharmaceutica NV (BE) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Seltorexant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Seltorexant | Argentina | AR078731 | 2029-10-23 | ⤷ Start Trial |
| Seltorexant | Argentina | AR114667 | 2029-10-23 | ⤷ Start Trial |
| Seltorexant | Australia | AU2010310595 | 2029-10-23 | ⤷ Start Trial |
| Seltorexant | Australia | AU2015242975 | 2029-10-23 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
